This report provides comprehensive insights about DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the DUPIXENT for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the DUPIXENT for CSU.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for CSU in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.
Drug Summary
DUPIXENT (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the ‘Type I’ receptor and both IL-4 and IL-13 signaling through the ‘Type II receptor’.
Multiple cell types that express IL-4Rα (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including releasing proinflammatory cytokines, chemokines, nitric oxide, and IgE.
DUPIXENT is approved for multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
- Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
- The report also highlights the DUPIXENT research and development activities in CSU across the United States, Europe, and Japan.
- The report also covers the patents information with expiry timeline around DUPIXENT.
- The report contains forecasted sales of DUPIXENT for CSU till 2032.
- Comprehensive coverage of the late-stage emerging therapies for CSU.
- The report also features the SWOT analysis with analyst views for DUPIXENT in CSU.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DUPIXENT Analytical Perspective
In-depth DUPIXENT Market Assessment
This report provides a detailed market assessment of DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
DUPIXENT Clinical Assessment
The report provides the clinical trials information of DUPIXENT for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
- Other emerging products for CSU are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in CSU.
- This in-depth analysis of the forecasted sales data of DUPIXENT from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in CSU.
Key Questions Answered
- What is the product type, route of administration and mechanism of action of DUPIXENT?
- What is the clinical trial status of the study related to DUPIXENT in Chronic Spontaneous Urticaria (CSU) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
- What are the key designations that have been granted to DUPIXENT for CSU?
- What is the forecasted market scenario of DUPIXENT for CSU?
- What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What are the other emerging products available and how are these giving competition to DUPIXENT for CSU?
- Which are the late-stage emerging therapies under development for the treatment of CSU?
This product will be delivered within 2 business days.
